首页 > 市场调查报告书 > 製药

癌症

胃癌药物市场规模、份额和成长分析（按治疗方法、疾病、药物类别和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1897224

胃癌药物市场规模、份额和成长分析（按治疗方法、疾病、药物类别和地区划分）—产业预测（2026-2033 年）

Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Treatment Type, By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor ), By Drug Class, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球胃癌药物市场规模预计在 2024 年达到 60.2 亿美元，从 2025 年的 67.1 亿美元增长到 2033 年的 160.4 亿美元，在预测期（2026-2033 年）内复合年增长率为 11.5%。

由于胃癌发病率不断上升和药物研发取得突破性进展，全球胃癌药物市场正经历显着增长。肥胖率上升、吸烟率上升、饮食习惯改变以及幽门螺旋桿菌病菌感染的广泛流行等因素，都促使人们对有效治疗方法的需求日益增长。包括标靶治疗和免疫疗法在内的药物创新正在革新诊断技术并改善患者预后。不断上涨的医疗成本、强劲的研发投入以及有利的法规环境进一步推动了市场扩张。然而，挑战依然存在，例如高昂的药物研发成本、严格的监管以及低收入社区药物取得的不公平性。儘管存在这些障碍，但专注于联合治疗、生物相似药和个人化医疗的丰富研发管线有望塑造胃癌药物市场的未来格局。

推动全球胃癌药物市场发展的因素

标靶治疗和免疫疗法的日益普及和核准，正显着推动全球胃癌治疗市场的成长。与传统化疗相比，HER2抑制剂和PD-1/PD-L1查核点抑制剂等创新疗法具有更高的疗效和安全性。这些先进治疗方法旨在针对特定的基因突变或免疫查核点，为治疗性介入创造了新的契机，并显着改善了相当一部分胃癌患者的治疗效果。随着大型临床试验不断证实这些新型治疗方法的优越性，监管机构和医疗专业人员的快速采纳正推动市场显着扩张。

限制全球胃癌药物市场的因素

新型标靶治疗和免疫疗法的高昂价格是全球胃癌治疗市场成长的一大障碍。这些先进疗法通常价格昂贵，反映了其庞大的研发成本、复杂的生产流程以及伴随诊断的必要性。因此，能否获得这些疗法主要取决于经济能力，这对中低收入国家的患者构成了重大障碍。此外，即使在高所得国家，医保报销的挑战和预算限制也会阻碍这些疗法的广泛应用。这些与成本相关的障碍阻碍了患者获得治疗，并减缓了整个市场的发展。

全球胃癌药物市场趋势

全球胃癌治疗市场正呈现出显着的趋势，即采用创新治疗方法和精准医疗。随着生物製药和标靶治疗的进步，医疗服务提供者正致力于为癌症患者量身定制个人化治疗方案，以满足其独特的基因特征。这项转变的驱动力在于研发活动的增加以及对早期诊断和介入策略日益重视。人工智慧等先进技术的融合正在提升药物研发流程和病患监测，从而改善治疗效果。随着人们对有效胃癌疗法的认识和需求不断提高，预计该市场将迎来强劲成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Imugene Limited（Australia）
Otsuka Pharmaceuticals Co., Ltd（Japan）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Bristol-Myers Squibb Company（US）
Novartis AG（Switzerland）
Lilly（US）
Sanofi（France）
Amgen Inc.（US）
Bayer AG（Germany）
Gilead Sciences, Inc.（US）
AstraZeneca（UK）
Ipsen Pharma（France）
Takeda Pharmaceutical Company Limited（Japan）
Biosplice Therapeutics, Inc.（US）
Arbutus Biopharma（Canada）
ASLAN Pharmaceuticals（Singapore）

结论与建议

简介目录

Product Code: SQMIG35I2393

Global Gastric Cancer Drugs Market size was valued at USD 6.02 Billion in 2024 and is poised to grow from USD 6.71 Billion in 2025 to USD 16.04 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The global market for gastric cancer drugs is experiencing significant growth driven by increasing incidence rates and groundbreaking advancements in drug development. Factors such as rising obesity, smoking rates, and dietary habits, coupled with the widespread prevalence of Helicobacter pylori infections, contribute to a higher demand for effective treatment options. Innovations in pharmaceuticals, including targeted therapies and immunotherapies, are transforming diagnostics and improving patient outcomes. Enhanced healthcare spending, robust R&D investments, and supportive regulatory environments further stimulate market expansion. However, challenges remain, including high drug development costs, stringent regulations, and access disparities in low-income regions. Despite these hurdles, a rich pipeline focusing on combination therapies, biosimilars, and personalized medicine is poised to shape the future landscape of the gastric cancer drug market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Cancer Drugs Market Segments Analysis

Global Gastric Cancer Drugs Market is segmented by Type, Treatment Type, Drug Type, Route of Administration, End-Users and region. Based on Type, the market is segmented into Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation Therapy, Medication and Others. Based on Drug Type, the market is segmented into Doxorubicin Hydrochloride, Sunitinib, Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Cancer Drugs Market

The rising availability and approval of targeted therapies and immunotherapies are significantly propelling growth in the global gastric cancer drug market. Innovations such as HER2 inhibitors and PD-1/PD-L1 checkpoint inhibitors offer enhanced efficacy and safety when contrasted with traditional chemotherapy methods. These advanced treatments are designed to specifically address actionable genetic mutations and immune checkpoints, thus creating new opportunities for therapeutic interventions and enhancing patient outcomes for a notable segment of the gastric cancer population. As pivotal clinical trials increasingly demonstrate the advantages of these novel treatments, their swift adoption by regulatory bodies and healthcare professionals is driving substantial market expansion.

Restraints in the Global Gastric Cancer Drugs Market

The elevated prices associated with novel targeted therapies and immunotherapies present a notable hurdle for growth in the Global Gastric Cancer Drugs market. These advanced treatments often come with premium price tags, reflecting substantial research and development expenditures, intricate manufacturing processes, and the necessity for companion diagnostics. As a result, access to these therapies is largely dependent on financial capability, posing a significant barrier to patients in low- and middle-income countries. Furthermore, even in high-income economies, reimbursement challenges and budgetary limitations can hinder broader adoption. Consequently, these cost-related barriers impede patient access and slow the overall advancement of the market.

Market Trends of the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market is witnessing a significant trend towards the adoption of innovative treatment modalities and precision medicine. With advancements in biologics and targeted therapies, healthcare providers are focusing on personalized treatment plans tailored to the unique genetic profiles of cancer patients. This shift is being driven by increased research and development activities, along with a growing emphasis on early diagnosis and intervention strategies. The integration of cutting-edge technologies, such as artificial intelligence, is enhancing drug discovery processes and patient monitoring, resulting in improved outcomes. As awareness and demand for effective gastric cancer treatments rise, the market is poised for robust growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies
Customer Buying Behavior Analysis

Global Gastric Cancer Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others

Global Gastric Cancer Drugs Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Surgery
Radiation Therapy
Medication
Others

Global Gastric Cancer Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Doxorubicin Hydrochloride
Sunitinib
Mitomycin
Imatinib
Fluorouracil
Trastuzumab
Others

Global Gastric Cancer Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable

Global Gastric Cancer Drugs Market Size by End-Users & CAGR (2026-2033)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Gastric Cancer Drugs Market Size & CAGR (2026-2033)

North America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- US
- Canada
Europe (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Imugene Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosplice Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ASLAN Pharmaceuticals (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments